GlassScriptPhysician profile
Kang Yang
NPI 1801527841
$2,435.46
in general payments reported to CMS, 2019-2025
17 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $347 · 2023: $701 · 2024: $1,167 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,088.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $496.16 | 2022-2025 | |
| Alkermes, INC. | $417.60 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $297.49 | 2022-2024 | Spravato, Invega Sustenna |
| Lundbeck LLC | $183.96 | 2022-2024 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $177.46 | 2022-2024 | Trintellix |
| Corium, LLC | $172.08 | 2022-2024 | Azstarys |
| Axsome Therapeutics, INC. | $134.09 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $126.46 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $117.44 | 2022-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $71.13 | 2023-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $67.66 | 2024 | Qelbree |
| Harmony Biosciences LLC | $61.67 | 2022 | |
| Almatica Pharma LLC | $29.68 | 2024 | Loreev Xr |
| Neurocrine Biosciences, INC. | $27.98 | 2023-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $22.86 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $16.36 | 2022 | |
| Braeburn INC. | $15.38 | 2024 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kang Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.